Skip to main content
  1. Right Decisions
  2. GGC - Clinical Guidelines
  3. Paediatrics
  4. Back
  5. Emergency Medicine (Paediatric)
  6. Adrenal insufficiency in children, emergency management protocol, paediatrics (239)
Please update your RDS mobile app to version 4.7.1

We are pleased to advise that deep linking capability, enabling users to directly download individual mobile toolkits, has now been released on the RDS mobile app. When you install the update, you will see that each toolkit has a small QR code icon the header area beside the search icon – see screenshot below. Clicking on this icon will open up a window with a full-size QR code and the alternative of a short URL for sharing with users. Instructions are provided.

You may need to actively install the update to install RDS app version 4.7.1 to see this improvement. Installing this update is also strongly recommended to get the full benefits of the new contingency arrangements – specifically, that if the RDS website should fail, you will still be able to download new mobile app toolkits. 

To check your current RDS version, click on the three dots bottom right of the RDS app screen. This takes you to a “More” page where you will see the version number.  To install latest updates:

On iPhones – go to the Apple store, click on your profile icon top right, scroll down to see the apps waiting to be updated and update the RDS app.

On Android phones – these can vary, but try going to the Google Play store, click on your profile icon top right, click on “Manage apps and device”, select and update the RDS app.

Please get in touch with ann.wales3@nhs.scot with any questions.

Adrenal insufficiency in children, emergency management protocol, paediatrics (239)

Warning

Objectives

Standardisation of the management of acutely unwell children with known adrenal insufficiency. 

Scope

This clinical protocol should be used in children with known adrenal insufficiency who present acutely unwell.

November 2023: This guidance is currently under review as it has gone beyond the standard review date. It reflects best practice at the time of authorship / last review and remains safe for use. If there are any concerns regarding the content then please consult with senior clinical staff to confirm.

Conditions: Children on daily replacement hydrocortisone treatment, eg.

  • Congenital Adrenal Hyperplasia
  • Congenital Adrenal Hypoplasia
  • Adrenal Insufficiency
  • Multiple Pituitary Hormone Deficiency

On Arrival in Emergency Department
Ensure Urgent Clinical Assessment and contact Endocrine team

  1. If child has an intercurrent illness, but is well, feeding, playing and tolerating medication normally, there is no need for increase in hydrocortisone.

  2. If child is unwell with fever and reduced activity, but tolerating oral medication, double largest daily hydrocortisone dose and administer three times per day for 48 hours. 
    (e.g. if normally on 10mg morning and 5mg evening – give 20mg three times/day - parents will usually be aware of their child’s emergency hydrocortisone regime.)

  3. If severely unwell- unresponsive/vomiting:
    • Check blood sugar and urea & electrolytes including full blood count
    • If capillary glucose <3mmol/l give 2ml/kg of 10% dextrose, repeat if BM remains low
    • Fluid bolus may also be required (10-20ml/kg 0.9% saline) if indicated.
    • Give IV hydrocortisone bolus (IM if delay in IV access) and start IV infusion (table below).
    • Start IV maintenance fluids + deficit (e.g. 5% dex/0.45% saline)
    • Consider double dose hydrocortisone therapy once able to tolerate oral medications

Child may already be on double hydrocortisone therapy and possibly
received intramuscular dose of hydrocortisone at home.
Beware clinical improvement may be due to IM hydrocortisone.

Age

Hydrocortisone Bolus 
[if no IM dose given]

Hydrocortisone infusion 
[50mg hydrocortisone in 50mls 0.9%saline]

<6months

12.5mg

1ml/hr

6 months-5years

25mg

1ml/hr

5-10years

50mg

2ml/hr

>10years

100mg

3ml/hr

DO NOT DISCHARGE HOME without discussing with endocrine team

Editorial Information

Last reviewed: 24/05/2022

Next review date: 31/10/2024

Author(s): Guftar Shaikh.

Version: 5

Approved By: Paediatric Clinical Effectiveness & Risk Committee

Document Id: 239